Search

Your search keyword '"Cannito, Stefania"' showing total 230 results

Search Constraints

Start Over You searched for: Author "Cannito, Stefania" Remove constraint Author: "Cannito, Stefania"
230 results on '"Cannito, Stefania"'

Search Results

1. The protease activated receptor 2 - CCAAT/enhancer-binding protein beta - SerpinB3 axis inhibition as a novel strategy for the treatment of non-alcoholic steatohepatitis

2. SAT-219 Discovering 1-piperidine propionic acid inhibiting effect on protease activated receptor 2 and serpinb3 as a new therapeutic strategy for metabolic dysfunction-associated steatohepatitis

5. Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.

6. The polymorphic variant of SerpinB3 (SerpinB3‐PD) is associated with faster cirrhosis decompensation

10. Inhibition of CCAT/enhancer-binding protein beta-serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis

11. Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC

12. The polymorphic variant of SerpinB3 (SerpinB3‐PD) is associated with faster cirrhosis decompensation.

13. SerpinB3 Upregulates Low-Density Lipoprotein Receptor-Related Protein (LRP) Family Members, Leading to Wnt Signaling Activation and Increased Cell Survival and Invasiveness

14. The CCAAT/Enhancer-Binding Protein Beta - SerpinB3 Axis Inhibition as a Novel Strategy for Non-Alcoholic Steatohepatitis Treatment

18. SerpinB3 as a Pro-Inflammatory Mediator in the Progression of Experimental Non-Alcoholic Fatty Liver Disease

19. G protein–coupled receptor 21 in macrophages: An in vitro study

22. Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses.

23. Oncostatin M is overexpressed in NASH‐related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis

24. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis

26. GPR21 Inhibition Increases Glucose-Uptake in HepG2 Cells

29. WED-449 - Inhibition of CCAT/enhancer-binding protein beta-serpinB3 axis by 1-piperidin propionic acid: a new targeted therapy for non-alcoholic steatohepatitis

34. SERPINB3 inhibition as a novel target therapy for non-alcoholic steatohepatitis

36. Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts

37. SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets

42. THU-464-NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2 alpha

44. Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts.

45. Hypoxia‐inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine‐rich glycoprotein

46. Hyaluronated mesoporous silica nanoparticles for active targeting: influence of conjugation method and hyaluronic acid molecular weight on the nanovector properties

47. Serpinb3 is overexpressed in the liver in presence of iron overload

48. SerpinB3 Promotes Pro-fibrogenic Responses in Activated Hepatic Stellate Cells

49. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis

50. SerpinB3 and Yap Interplay Increases Myc Oncogenic Activity

Catalog

Books, media, physical & digital resources